^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PODXL (Podocalyxin)

    i
    Other names: Podxl, Podocalyxin, PCLP-1, GCTM-2 Antigen , Podocalyxin-Like Protein 1
    4d
    Structural and Dynamic Insights into Podocalyxin-Ezrin Interaction as a Target in Cancer Progression. (PubMed, J Xenobiot)
    Through virtual screening, we identified NSC305787 as a selective destabiliser of the R495W mutant complex by disrupting key Trp495-pre-C-terminal loop Ezrin interactions and causing steric hindrance to PIP2 recruitment. Our findings identified mutation-dependent changes in drug binding that can guide the development and repurposing of compounds for targeting PODXL-related cancers and improve patient outcomes in PODXL-altered malignancies.
    Journal
    |
    EZR (Ezrin) • PODXL (Podocalyxin)
    |
    NSC305787
    7d
    Can Podocalyxin Immunoreactivity Facilitate Histopathological Diagnosis of Placenta Accreta Spectrum (PAS) Disorders? (PubMed, J Obstet Gynaecol Res)
    In PAS cases undergoing clinical hysterectomy, the increase in PCX immunoreactivity can be used as an immunohistochemical marker to support the diagnosis of PAS in histopathological confirmation of PAS diagnosis.
    Journal
    |
    PODXL (Podocalyxin)
    2ms
    Renal podocyte senescence in human obesity detected by urinary extracellular vesicles. (PubMed, EBioMedicine)
    Human obesity induces in persons with normal kidney function podocyte senescence, which is detectable non-invasively by uEVs.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • KIM1 (Kidney injury molecule 1) • LCN2 (Lipocalin-2) • PODXL (Podocalyxin)
    3ms
    Biomimetic core-shell breast cancer models using alginate, gelatin, and collagen I: simulating the tumor matrix for drug evaluation. (PubMed, Int J Biol Macromol)
    Breast cancer cells proliferated in the core of all prototypes designed, forming spheroids and cell aggregates with a high resistance to doxorubicin. The addition of Collagen I to the developed model enabled the upregulation of malignancy markers (Col1A1, Ki67, FOXC2, SNAI1, NFKB1, WWTR1), invasion markers (WASL, ACTA1, MYO1E, TPM4, PODXL, ITGA2, ITGA5, MENA, EGFR, CDC42), and drug resistance markers (ABCG2, CYP1A1, BAX, HSP90AA1) occurring in vivo. The developed 3D in vitro model can clarify the contribution of the extracellular matrix to the tumor outcome and drug efficacy by replicating some key characteristics of breast tumors, establishing a novel tool for chemotherapeutic agents and drug screening.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • COL1A1 (Collagen Type I Alpha 1 Chain) • WWTR1 (WW Domain Containing Transcription Regulator 1) • CDC42 (Cell Division Cycle 42) • PODXL (Podocalyxin) • SNAI1 (Snail Family Transcriptional Repressor 1) • TPM4 (Tropomyosin 4) • ACTA1 (Actin Alpha 1, Skeletal Muscle) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • ITGA2 (Integrin Subunit Alpha 2) • ITGA5 (Integrin Subunit Alpha 5) • FOXC2 (Forkhead Box C2)
    |
    doxorubicin hydrochloride
    4ms
    Advancements in single-cell sequencing for cervical cancer research. (PubMed, Mol Cell Biochem)
    Future efforts must prioritize functional validation of novel targets (DKK2, ELF3), spatial multi-omics to resolve CAF-immune-metabolic crosstalk, and biomarker-driven clinical trials integrating single-cell classifiers. By bridging single-cell insights with mechanistic and translational studies, the field can overcome stromal-mediated resistance and usher in an era of precision immunotherapy for CC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • SPP1 (Secreted Phosphoprotein 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ELF3 (E74 Like ETS Transcription Factor 3) • SALL4 (Spalt Like Transcription Factor 4) • PODXL (Podocalyxin) • PCLAF (PCNA Clamp Associated Factor)
    4ms
    Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction. (PubMed, BMC Cancer)
    Collectively, these data suggest that PODXL may play an important role in aiding immune evasion in HGSC, at least partly by conferring resistance to NK cell infiltration and the related cytotoxicity.
    Journal
    |
    CD34 (CD34 molecule) • PODXL (Podocalyxin)
    4ms
    Novel molecular biomarkers in kidney diseases: bridging the gap between early detection and clinical implementation. (PubMed, J Pharm Pharmacol)
    These biomarkers may enhance early diagnosis, enable personalized therapy, and improve kidney disease outcomes. Their integration into clinical practice may bridge the gap between early detection and effective intervention, potentially improving long-term outcomes in patients with kidney disease.
    Journal
    |
    KIM1 (Kidney injury molecule 1) • LCN2 (Lipocalin-2) • MRC1 (Mannose Receptor C-Type 1) • PODXL (Podocalyxin) • SESN2 (Sestrin 2) • USP18 (Ubiquitin Specific Peptidase 18)
    6ms
    A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (humPcMab-60) Demonstrated Antitumor Efficacy in Pancreatic and Colorectal Cancer Xenograft Models. (PubMed, Antibodies (Basel))
    Furthermore, humPcMab-60 exerted antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against PODXL-expressing cell lines and showed antitumor effects against the tumor xenografts. A humanized anti-PODXL CasMab, humPcMab-60, could be a promising mAb-based tumor therapy.
    Preclinical • Journal
    |
    PODXL (Podocalyxin)
    7ms
    Thin endometrium restricts peri-ovulatory physiological transition between anti-adhesive and adhesive receptivity modulators. (PubMed, Reprod Biomed Online)
    Endometrial thinning causes defective expression of anti-adhesive and adhesive receptivity modulators, restricting the transition of the endometrium from a non-receptive to a receptive state.
    Journal
    |
    HOXA11 (Homeobox A11) • PODXL (Podocalyxin) • HOXA10 (Homeobox A10)
    8ms
    Luteolin prevents axitinib-induced kidney damage in mice. (PubMed, Chem Biol Interact)
    Our results elucidate that axitinib induces podocyte filtration barrier core protein loss, foot process effacement, glomerulosclerosis, and proteinuria through upregulation of TRPC6 protein expression. Additionally, naturally derived luteolin serves as a potential intervention strategy, providing a theoretical basis for the clinical prevention and treatment of nephrotoxicity caused by axitinib and other TKIs.
    Preclinical • Journal
    |
    PODXL (Podocalyxin) • TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6)
    |
    axitinib
    8ms
    The Aging Epigenome: Integrative Analyses Reveal Functional Overlap with Alzheimer's Disease. (PubMed, medRxiv)
    Finally, we prioritized 9 aging-associated CpGs, located in promoter regions of PDE1B, ELOVL2, PODXL2 , and other genomic regions, that showed strong positive blood-to-brain methylation concordance, as well as association with AD or AD neuropathology in independent studies, after adjusting for age and other covariates. Our findings provided insights into the functional overlap between the aging processes and AD, and nominated promising blood-based biomarkers for future AD research.
    Journal
    |
    PODXL (Podocalyxin)
    10ms
    Multi-omic features and clustering phenotypes of circulating tumor cells associated with metastasis and clinical outcomes. (PubMed, Int Rev Cell Mol Biol)
    This chapter mainly focused on CTC biology related to multi-omic features and metastatic outcomes. We speculate that CTCs could guide therapeutic targeting and be targeted specifically by anti-CTC therapeutics to reduce or eliminate cancer and cancer metastasis.
    Clinical data • Review • Journal • Circulating tumor cells
    |
    ICAM1 (Intercellular adhesion molecule 1) • PODXL (Podocalyxin) • CD81 (CD81 Molecule)